Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | PHASE3 | NOT YET_RECRUITING | 740 | — | — | Dec 1, 2025 | Jul 1, 2030 | Sep 3, 2025 | - | — |
Overall survival (OS), defined as the time from randomization to death from any cause up to 60 months.
| Arm | Type | Description |
|---|---|---|
| Active Arm | EXPERIMENTAL | TPST-1120 600 mg by mouth (PO) twice daily (BID) with atezolizumab 1200 mg intravenously (IV) every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W |
| Control Arm | ACTIVE_COMPARATOR | Placebo tablets PO BID with atezolizumab 1200 mg IV Q3W and bevacizumab 15 mg/kg IV Q3W |
| Name | Type | Description |
|---|---|---|
| TPST-1120 | DRUG | TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα) |
| Atezolizumab | BIOLOGICAL | Atezolizumab is an IV administered biologic. |
| Bevacizumab | BIOLOGICAL | Bevacizumab is an IV administered biologic. |
Inclusion Criteria: 1. Written informed consent 2. Age ≥ 18 years at the time of signing ICF 3. HCC diagnosis confirmed by histology/cytology or clinically by the American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients a) Patients without cirrhosis require hi...